Trade Mark Journal No.2025/046 14 November 2025

WO0000001883513 (5)

Office of origin: United States of America

Date of International Registration:16 September 2025
Date of designation in the UK: 16 September 2025
Image for mark 1883513 MYOFORMIN

International priority date claimed: 19 March 2025 (United States of America) (99092562)
Class 5
Pharmaceutical preparations for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications or conditions or complications associated with any of the foregoing; nutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; nutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength.

Emmyon, Inc.

Representative: Erica M Hines Heslin Rothenberg Farley & Mesiti PC, 5 Columbia Circle, Albany NY 12203, UNITED STATES OF AMERICA